{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:36:48Z","timestamp":1790030208942,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejrad.2025.112614","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:31:09Z","timestamp":1765593069000},"page":"112614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Predictive value of quantitative parameters from dual-tracer FDG and PSMA PET\/CT for progression to castration resistance in patients with metastatic hormone-sensitive prostate cancer"],"prefix":"10.1016","volume":"195","author":[{"given":"Fangzheng","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fufu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10305","key":"10.1016\/j.ejrad.2025.112614_b0005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer[J]","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ejrad.2025.112614_b0010","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer[J]","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejrad.2025.112614_b0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer[J]","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ejrad.2025.112614_b0020","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study[J]","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ejrad.2025.112614_b0025","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00345-022-04134-9","article-title":"Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer[J]","volume":"41","author":"Matsumura","year":"2023","journal-title":"World J. Urol."},{"issue":"6","key":"10.1016\/j.ejrad.2025.112614_b0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review[J]","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol."},{"issue":"155","key":"10.1016\/j.ejrad.2025.112614_b0035","first-page":"56","article-title":"Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.[J]. European journal of cancer (Oxford","volume":"2021","author":"Caffo","year":"1990","journal-title":"England"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112614_b0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur. Urol."},{"issue":"10231","key":"10.1016\/j.ejrad.2025.112614_b0045","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study[J]","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejrad.2025.112614_b0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer[J]","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112614_b0055","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","article-title":"Flare on [18F]PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients[J]","volume":"50","author":"Malaspina","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112614_b0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/RLU.0000000000005587","article-title":"Dual-Tracer 18F-FDG and 68Ga-PSMA PET\/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy[J]","volume":"50","author":"Bian","year":"2025","journal-title":"Clin. Nucl. Med."},{"issue":"6","key":"10.1016\/j.ejrad.2025.112614_b0065","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00259-023-06585-7","article-title":"Combination of [18F]FDG and [18F]PSMA-1007 PET\/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer[J]","volume":"51","author":"Kim","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112614_b0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2967\/jnumed.116.181768","article-title":"Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging[J]","volume":"58","author":"Cardinale","year":"2017","journal-title":"Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112614_b0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?[J]","volume":"52","author":"Im","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2025.112614_b0080","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231208960","article-title":"Current role of PSMA-PET imaging in the clinical management of prostate cancer[J]","volume":"15","author":"Georgakopoulos","year":"2023","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"9","key":"10.1016\/j.ejrad.2025.112614_b0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12149-023-01854-9","article-title":"Role of volumetric parameters obtained from 68Ga-PSMA PET\/CT and 18F-FDG PET\/CT in predicting overall survival in patients with mCRPC receiving taxane therapy[J]","volume":"37","author":"G\u00fczel","year":"2023","journal-title":"Ann. Nucl. Med."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112614_b0090","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.21873\/invivo.13211","article-title":"68Ga-PSMA PET\/CT and Prostate Cancer Diagnosis: Which SUVmax Value?[J]","volume":"37","author":"Pepe","year":"2023","journal-title":"In Vivo"},{"issue":"8","key":"10.1016\/j.ejrad.2025.112614_b0095","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2967\/jnumed.120.256602","article-title":"Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study[J]","volume":"62","author":"Wibmer","year":"2021","journal-title":"Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine"},{"key":"10.1016\/j.ejrad.2025.112614_b0100","article-title":"Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial[J]. European Urology","author":"Hofman","year":"2024","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.ejrad.2025.112614_b0105","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1007\/s00432-022-04438-8","article-title":"Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage[J]","volume":"149","author":"Ke","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112614_b0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting[J]","volume":"8","author":"Ng","year":"2020","journal-title":"Oncology and Therapy"},{"key":"10.1016\/j.ejrad.2025.112614_b0115","doi-asserted-by":"crossref","unstructured":"SCHMUCK S, KLOT C A von, HENKENBERENS C, et al. Initial Experience with Volumetric 68Ga-PSMA I&T PET\/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer[J]. Journal of Nuclear Medicine, 2017, 58(12): 1962-1968.","DOI":"10.2967\/jnumed.117.193581"},{"issue":"9","key":"10.1016\/j.ejrad.2025.112614_b0120","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1007\/s00259-021-05221-6","article-title":"Diagnostic value of 18F-FDG PET\/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET\/CT[J]","volume":"48","author":"Chen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112614_b0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/diagnostics14010007","article-title":"18F-FDG PET Is Not Inferior to 68Ga-PSMA PET for Detecting Biochemical Recurrent Prostate Cancer with a High Gleason Score: A Head-to-Head Comparison Study[J]","volume":"14","author":"Xu","year":"2023","journal-title":"Diagnostics"},{"issue":"2\u20133","key":"10.1016\/j.ejrad.2025.112614_b0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","article-title":"The SLC2 (GLUT) family of membrane transporters[J]","volume":"34","author":"Mueckler","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ejrad.2025.112614_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2020.05.007","article-title":"GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers[J]","volume":"485","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejrad.2025.112614_b0140","unstructured":"REINFELD B, MADDEN M, WOLF M, et al. Cell Programmed Nutrient Partitioning in the Tumor Microenvironment[EB\/OL]. (2020-08-10)[2025-02-10]. http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2020.08.10.238428."},{"issue":"7858","key":"10.1016\/j.ejrad.2025.112614_b0145","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment[J]","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejrad.2025.112614_b0150","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.20892\/j.issn.2095-3941.2020.0550","article-title":"Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer[J]","volume":"19","author":"Wang","year":"2022","journal-title":"Cancer Biol. Med."},{"issue":"12","key":"10.1016\/j.ejrad.2025.112614_b0155","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","article-title":"PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease[J]","volume":"62","author":"Barbato","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ejrad.2025.112614_b0160","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/RLU.0000000000004763","article-title":"Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel[J]","volume":"48","author":"Shagera","year":"2023","journal-title":"Clin. Nucl. Med."},{"issue":"11","key":"10.1016\/j.ejrad.2025.112614_b0165","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial[J]","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112614_b0170","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00259-022-05971-x","article-title":"The role of quantitative tumor burden based on [68 Ga]Ga-DOTA-NOC PET\/CT in well-differentiated neuroendocrine tumors: beyond prognosis[J]","volume":"50","author":"Chen","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25007004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25007004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:53:30Z","timestamp":1771642410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X25007004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"alternative-id":["S0720048X25007004"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112614","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of quantitative parameters from dual-tracer FDG and PSMA PET\/CT for progression to castration resistance in patients with metastatic hormone-sensitive prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112614"}}